Darrell White

9.1k total citations
134 papers, 1.9k citations indexed

About

Darrell White is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Darrell White has authored 134 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Hematology, 77 papers in Molecular Biology and 67 papers in Oncology. Recurrent topics in Darrell White's work include Multiple Myeloma Research and Treatments (116 papers), Protein Degradation and Inhibitors (53 papers) and Cancer Treatment and Pharmacology (34 papers). Darrell White is often cited by papers focused on Multiple Myeloma Research and Treatments (116 papers), Protein Degradation and Inhibitors (53 papers) and Cancer Treatment and Pharmacology (34 papers). Darrell White collaborates with scholars based in Canada, United States and Spain. Darrell White's co-authors include Donna Reece, Andrew R. Belch, Philippe Moreau, Nizar J. Bahlis, Tony Reiman, Lotfi Benboubker, Meletios Α. Dimopoulos, A. Keith Stewart, Paul G. Richardson and Christine I. Chen and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Darrell White

126 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darrell White Canada	23	1.3k	1.0k	998	456	311	134	1.9k
Leonard T. Heffner United States	21	996 0.8×	784 0.8×	856 0.9×	464 1.0×	561 1.8×	86	1.8k
William Deraedt United States	15	2.2k 1.8×	1.5k 1.5×	1.7k 1.7×	199 0.4×	410 1.3×	56	2.7k
Hyeon‐Seok Eom South Korea	24	530 0.4×	864 0.9×	412 0.4×	679 1.5×	301 1.0×	133	1.7k
Leonard T. Heffner United States	21	1.1k 0.8×	717 0.7×	687 0.7×	214 0.5×	299 1.0×	68	1.7k
Laurent Voillat France	20	1.9k 1.5×	1.3k 1.3×	1.4k 1.4×	380 0.8×	261 0.8×	47	2.4k
Parameswaran Venugopal United States	21	1.1k 0.8×	412 0.4×	684 0.7×	339 0.7×	482 1.5×	130	1.9k
Sylvia Feyler United Kingdom	16	1.5k 1.2×	1.3k 1.3×	847 0.8×	161 0.4×	191 0.6×	25	2.2k
Ana Balanzategui Spain	25	491 0.4×	459 0.5×	440 0.4×	539 1.2×	492 1.6×	70	1.5k
Kay Delasalle United States	31	2.6k 2.1×	1.6k 1.6×	1.7k 1.7×	643 1.4×	953 3.1×	61	3.4k
Claudia Cellini Italy	20	1.2k 0.9×	813 0.8×	862 0.9×	286 0.6×	271 0.9×	30	1.6k

Countries citing papers authored by Darrell White

Since Specialization

Citations

This map shows the geographic impact of Darrell White's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darrell White with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darrell White more than expected).

Fields of papers citing papers by Darrell White

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darrell White. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darrell White. The network helps show where Darrell White may publish in the future.

Co-authorship network of co-authors of Darrell White

This figure shows the co-authorship network connecting the top 25 collaborators of Darrell White. A scholar is included among the top collaborators of Darrell White based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darrell White. Darrell White is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Venner, Christopher P., Peter Duggan, Kevin Song, et al.. (2024). Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database. Transplantation and Cellular Therapy. 30(9). 889–901. 1 indexed citations

McCurdy, Arleigh, Donna Reece, Martha Louzada, et al.. (2024). Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. Blood Cancer Journal. 14(1). 155–155. 2 indexed citations

Lancman, Guido, Kevin Song, Darrell White, et al.. (2024). Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement. Frontiers in Oncology. 14. 1446995–1446995. 2 indexed citations

Eagles, Jenna, Aimée A. Wong, Saumil Shah, et al.. (2024). Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma. Blood. 144(Supplement 1). 3338–3338.

McCurdy, Arleigh, Donna Reece, Christopher P. Venner, et al.. (2023). Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 142(Supplement 1). 3364–3364. 1 indexed citations

Usmani, Saad Z., María‐Victoria Mateos, Vânia Hungria, et al.. (2020). Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. Journal of Cancer Research and Clinical Oncology. 147(2). 619–631. 20 indexed citations

Kukreti, Vishal, Donna Reece, Esther Masih‐Khan, et al.. (2020). The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. Haematologica. 106(6). 1733–1736. 8 indexed citations

Kaufman, Jonathan L., Saad Z. Usmani, Jesús F. San Miguel, et al.. (2019). Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1866–1866. 28 indexed citations

Dimopoulos, Meletios Α., Jonathan L. Kaufman, Darrell White, et al.. (2018). A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clinical Lymphoma Myeloma & Leukemia. 18(3). 163–173.e6. 18 indexed citations

10.

White, Darrell, Nizar J. Bahlis, Christopher P. Venner, et al.. (2017). A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 130. 1861–1861. 4 indexed citations

11.

Bahlis, Nizar J., Heather J. Sutherland, Darrell White, et al.. (2017). Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM). Blood. 130. 3135–3135.

12.

Gasparetto, Cristina, Suzanne Lentzsch, Gary J. Schiller, et al.. (2017). A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs). Blood. 130. 3100–3100. 2 indexed citations

13.

Chen, Christine I., Heather J. Sutherland, Rami Kotb, et al.. (2017). Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure. Blood. 130. 3136–3136. 3 indexed citations

14.

Dimopoulos, Meletios Α., David S. Siegel, Darrell White, et al.. (2017). Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study. Blood. 130. 1845–1845. 2 indexed citations

15.

White, Darrell, Nizar J. Bahlis, Andrew R. Belch, et al.. (2012). Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. Clinical Lymphoma Myeloma & Leukemia. 13(1). 19–24. 2 indexed citations

16.

Rieger, Michael A., Anders Österborg, Ruth Pettengell, et al.. (2010). Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Annals of Oncology. 22(3). 664–670. 139 indexed citations

17.

Dueck, Greg, Neil Chua, Daygen L. Finch, et al.. (2010). Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphoma. Cancer. 116(19). 4541–4548. 76 indexed citations

18.

Reece, Donna, Heather A. Leitch, Harold Atkins, et al.. (2008). Treatment of relapsed and refractory myeloma. Leukemia & lymphoma. 49(8). 1470–1485. 12 indexed citations

19.

Kew, Andrea, Stephen Couban, Ward Patrick, Kara Thompson, & Darrell White. (2006). Outcome of Hematopoietic Stem Cell Transplant Recipients Admitted to the Intensive Care Unit. Biology of Blood and Marrow Transplantation. 12(3). 301–305. 35 indexed citations

20.

Williams, Geoffrey S., et al.. (2005). Intravascular T-cell lymphoma with bowel involvement: Case report and literature review. American Journal of Hematology. 78(3). 207–211. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact